$7.32 Million in Sales Expected for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) This Quarter
Analysts forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce sales of $7.32 million for the current quarter, Zacks reports. Three analysts have provided estimates for Pieris Pharmaceuticals’ earnings. The highest sales estimate is $9.01 million and the lowest is $5.10 million. Pieris Pharmaceuticals reported sales of $11.69 million during the same quarter last year, which would suggest a negative year over year growth rate of 37.4%. The firm is expected to report its next earnings results on Thursday, August 8th.
On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.24 million for the current fiscal year, with estimates ranging from $20.40 million to $35.58 million. For the next fiscal year, analysts anticipate that the firm will report sales of $25.46 million, with estimates ranging from $13.33 million to $34.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The firm had revenue of $8.55 million during the quarter, compared to analyst estimates of $7.85 million. Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%.
Shares of PIRS traded up $0.35 during mid-day trading on Monday, hitting $4.75. The stock had a trading volume of 583,259 shares, compared to its average volume of 270,476. The stock has a market capitalization of $216.26 million, a P/E ratio of -9.50 and a beta of 1.25. The company’s fifty day moving average price is $4.45. Pieris Pharmaceuticals has a fifty-two week low of $2.39 and a fifty-two week high of $5.85.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers grew its stake in shares of Pieris Pharmaceuticals by 51.5% during the 4th quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 22,720 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $43,000. Dimensional Fund Advisors LP acquired a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $374,000. Two Sigma Investments LP acquired a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $159,000. Finally, Bank of America Corp DE grew its stake in shares of Pieris Pharmaceuticals by 793.1% during the 4th quarter. Bank of America Corp DE now owns 277,370 shares of the biotechnology company’s stock worth $739,000 after purchasing an additional 246,312 shares during the period. 59.70% of the stock is currently owned by institutional investors and hedge funds.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.